RheumaGen
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
RheumaGen is a private biotechnology company engineering a new class of cell and gene therapies designed to cure autoimmune diseases at their source. The company's breakthrough approach focuses on editing the human leukocyte antigen (HLA), or 'immune gene,' to prevent the immune system from attacking healthy cells. Founded in 2019, RheumaGen aims to deliver one-time, curative treatments for refractory autoimmune conditions.
RNA & Gene TherapyCell & Gene Therapy